



(51) International Patent Classification:

C07D 237/24 (2006.01) **C07D 405/10** (2006.01)
C07D 401/04 (2006.01) **C07D 405/12** (2006.01)
C07D 401/08 (2006.01) **C07D 409/10** (2006.01)
C07D 401/10 (2006.01) **C07D 409/12** (2006.01)
C07D 401/12 (2006.01) **C07D 413/06** (2006.01)
C07D 403/04 (2006.01) **C07D 471/04** (2006.01)
C07D 403/06 (2006.01) **C07D 473/00** (2006.01)
C07D 403/08 (2006.01) **C07D 487/04** (2006.01)
C07D 403/10 (2006.01) **C07D 487/14** (2006.01)
C07D 403/12 (2006.01) **C07D 487/22** (2006.01)
C07D 405/04 (2006.01) **C07D 498/04** (2006.01)
C07D 405/06 (2006.01) **C07D 498/22** (2006.01)

(21) International Application Number:

PCT/US2014/055018

(22) International Filing Date:

10 September 2014 (10.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/877,171 12 September 2013 (12.09.2013) US

(71) Applicant: **ALIOS BIOPHARMA, INC.** [US/US]; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: **BEIGELMAN, Leonid**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

HENDRICKS, Robert, Than; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **STOYCHEVA, Antitsa, Dimitrova**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **DEVAL, Jerome**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **STEVENS, Sarah, Katherine**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(74) Agent: **MILLER, Kimberly, J.**; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).




(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: PYRIDAZINONE COMPOUNDS AND USES THEREOF

Figure 1

Name or CAS No.	IUPAC Name	Structure
amantadine	adamantan-1-amine	
rimantadine	(1R,2R)-1-(1-adamantyl)ethanamine	
zanamivir	(2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid	
oseltamivir	ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate	

(57) Abstract: Disclosed herein are pyridazinone compounds, pharmaceutical compositions that include one or more pyridazinone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with a pyridazinone compounds. Examples of an orthomyxovirus viral infection includes an influenza infection.

WO 2015/038660 A1



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with sequence listing part of description (Rule 5.2(a))*
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*